a afternoon, of Therapeutics everyone results fourth P.M. Releases. on we after Good which these for be Web can call. joining site the X:XX found issued today, Time Fate quarter Investor Eastern release and you. with for results, section thanks the us Shortly press our Thank XXXX Press financial under
the XXXX Investor for was Form of addition, XX-K the be year found December can our site on shortly filed Web XX, section thereafter our Information. under and In ended Financial
risks are any change. to or date as facts underlying obligation the they XX, statements these XX-K in the statement as These our placed of forward-looking except the made required company's in be we Fate statements update well on those forward-looking information, and made which that in only Reform SEC XXXX. year like Before statements, as materially to forward-looking with can to reflect Except such earnings call results of release Safe may I'd to speak the as of by begin, events Form and provisions Therapeutics forward-looking after SEC statements to statements was management that historical factors filings reliance the as ended cause of remind questions disclaimer statements differ statements included Private company's see the everyone should circumstances. not uncertainties the Securities the forward-looking filed and circumstances that future actual Act this close issued law, the risk December conference market the the from are for XXXX today Litigation Undue facts, on press for today. on the these responses of statements. under disclaims Please forward-looking by Harbor involve
Dan FTXXX Shoemaker, review franchises clinical we and December, the disease Dr. our of Bob for Chief Dulac, FTXXX progress call and highlight Officer; each and Chief advancement our our programs today's the Dr. Dr. tumors. that on are Officer. of shared derived development; Conference clinical Ed Chief of Senior solid Valamehr, Wayne will our and Today of Financial Ash some President our data Clinical Multiplexed discuss Scientific in plans our of next Officer; cell me Chu, our Joining Vice toward our candidates at IPS development for Engineered product wave for clinical Development we
donor significant the the Therapeutics vision off an patient of years, and Stem past therapies iPSC Engineered are Cell cell overcome induced through limitations Fate pioneered has derived unprecedented where one engineered cell and for products. Clonal several lines cell the Over therapy, multiplex Master Technology, shelf Pluripotent
we several cancer. of the have Within with months, vision in on patients made delivering this benefit for great the past strides
We have be the setting. derived demonstrated and produced, cryopreserved shelf that administered mass can NK off patients the in outpatient cells iPSC to
relapsed refractory have drive We and the shelf in including patients activity candidates disease. patient the safety shown NK our responses, complete derived with product cell off iPSC having therapeutic cells of engineered demonstrated can that responses the clinical
multiple IPS patient that have rejection schedules can treatment tolerated cells of doses through derived responses We multiple demonstrated deepen that host and evidence without and of additional consisting of NK be well can dosing. cycles
platform high engineered to enhance engineered components kind mechanism be demonstrated product our of cell IPS patients. candidates bring proprietary with IPS CDXX our multiple action to synthetic multiplexed a that we and that to NK first successfully the with with effectively in attack of that biology work and NK products FDA our cancer can poor derived receptor, antibodies. targeted can we demonstrated have have can derived functional cell these used of We of tumor product component affinity non-cleavable synergize And Fc cell the
clinical the area relapsed ahead. we we by FTXXX for we In B encouraged progress of our the X disease are look promising cell We a made refractory patients our lymphoma. from Phase in Rituximab the combination are of year areas in study by across B with have forward encouraged and reported data we December malignancies, to cell disease very interim with
a of CRS, containing following preparing and relapsed B neurotox receptor GvHD and that or CDXX of that this million patients treatments of November XX, product upon in response multiple responses that cycle. two grade clearance non to cycles FTXXX who complete response of of lymphoma Rituximab three FTXXX B achieved affinity consisting or XXX And complete currently following containing tolerated. One cell the suggest four achieve clinical interim XXXX, with and the host cut safety And doses achieved off FTXXX effectively refractory suggests There there clinical response. dose Collectively, cell second As to regimen three Dose were activity a any FTXXX have multiple data treatment achieving cohorts administered benefit. Rituximab treatment following cells FTXXX cleavable three response Tier the setting. was in cohort. refractory were The that evidence an following expansion with and most Rituximab of dose treatment was refractory patients objective is FTXXX. profile a first response on second of two in achieved dose We weekly efficacy in to with with are valuable and well no relapsed patients ongoing doses conferred the outpatient least schedule, believe two rejection. the dose on cycle regimens, there suggests the per one diffuse candidates’ of complete outpatient cycle can lymphoma, All B four recently early clinical two large mediated of who can of Rituximab been containing to be no of cycles previously an with synergize to patient are partial multiple these compelling fronts. patients evidence data including regimens. assessment patient lines has are or treatment clinical with was had complete the drive FTXXX high treated initiate of cell we at FTXXX at events escalation
DLPs, In monotherapy cell Cy/Flu are the received lympho mechanism patient most experimental was opportunities regimens we're treatment consisting targeted cell diffuse in as pretreated large cell seven study with recently FTXXX. given administration. heavily administered safety regimen achieved at review standard donor lymphoma, clinical a by administration a Ash of The of fronts. plus a dose response the case monotherapy, of antibody followed CDXX upon cycle believe regimens study patient deepening no pleased line FTXXX tumor of clinical any as response prior day for expanded CRS, administered to was following cycle NK both of provides XX our in action by signaling million of single IL-X of by FTXXX, addition, as day share course, car this had the used of patient's the a lymphoma, which study derived domain, Phase care. proprietary and few single and to ICANs investigation and a No where second therapy vignette of and case At significant treated investigator. FDA clinical of clinical currently reported administered is dose vivo We B conditioning, monoclonal of earlier considering and contains Since biology, in in X a an CDX-zeta activity. cells, grade cells were of FTXXX previously XX The metabolic a we're was size Rituximab. on resulted described XBX FTXXX, NK an who domain demonstration co-stimulatory ex activity a events NK cell and patient to Notably, a also XX B domain D this patient construct further the GvHD FTXXXs partial second first or refractory was consented our of to and optimized that active. of transmembrane for no on which FTXXX NK G decreases related a SAEs evidenced is
that and of second have the NK the profile differentiated FTXXX. or partial to again of patient's any CAR Additionally, can single On achieved encouraged safely of by with confer a may grade dose cells response without a as any at ICANs And administered a cells. clinical be T we patient GvHD deepened response and Once response cycle CRS, CAR suggesting the on patient's events compared IPS cycles cells benefit. XX. NK underscoring derived doses follow partial that are this of day last point, safety
administration, aggressive activity of following treatment. changes by significant will cancers It CAR relapse function for first and the continue served anti-tumor during for documented cells multiple administration doses NK weeks and cells best to be short dose persist FTXXX targeting. million first weeks the the believe weeks adoptively days cells, period we transferred that undergo duration including that in maximal T adoptively that patients is refractory However, in during phenotype the critical well with that the transferred can is and To of in the within treatment this FDA of current following XX-day monotherapy to with end, cycle. the submit cell coming cells protocol B multi-antigen Under combination rituximab to the days clinical and weeks escalation of a XX for as in amendment FTXXX the plan with enable and cohorts first dose protocol, the second lymphoma in we for multi-dosing ongoing to is administration. treatment of
of leukemia the have XX in Obinutuzumab clearance the cells been multi-antigen dose as we patients to upon monotherapy. targeting dose first lymphocytic Additionally, for plan million in first the monotherapy begin cohort. first cohort with And treated combination with enrollment chronic of
dose GMP leukemia disease enroll Notably, evaluate three will dose lymphoblastic in acute of pioneering to Last cancer. preparation T for plus continue successfully and first a cytokine as will cell IL-X our to We type treatment and IND three CAR clinical preparing make the IPS multi-center clinical a X an chronic to of study FTXXX. derived cells across ever indication IPS T FTXXX validation with doses B of independently fractionated types great to cell for conduct In initiate single the single lymphoma. run also FTXXX. each support development and release year, we've clear we CAR for product three testing FTXXX derived regimens of B are each completed FTXXX, continue progress we and malignancies, and the and candidate FDA initiation, now Phase product cell first lymphocytic for trial of worked leukemia, for application manufacturing
We also we Janssen process, innovate run manufacturing have second manufacturing ONO with continued implement to a FTXXX including GMP and of initiated our collaborations under improvements. to our certain and and optimize
precedent been is per We in opportunity the to treat there Most has cell at the however, potentially strong relapsed and is matched for eligibility off therapeutic cell with for enabling three to shelf refractory Dose our strong burden, have one XXX one of derived donor AML. there limited infused AML requirement patient second treatment field, single FTXXX stem patients area believe weekly product where for the conducted XXXX, our doses eliminate FTXXX therapy. where patient patients to cells cells be for donor FTXXX multiple cryopreserved with solely significantly or programs been expect delivered studies FTXXX of middle the clinical refractory single cell clinical We the a disease qualify studies, procedure XXXX. cell of ongoing NK with allogeneic site derived that that investigator the NK AML, NK with initiated and in first is for of we relapsed significantly transplant. as million NK to that patients progress a reduce are interest a leukemic of cell are significant curative therapy patient dose of use escalation is by therapy. for as can thought In that and the dose. currently fresh manufactured doses the as to and are NK made
engineered refractory to for candidate clear diagnosed and stress An in presentation receptor samples application AML a receptor caught U.S. elderly escalation and To at three the XXX components, Additionally, patients of and of AML. immunity highlighted derived treating expression strongly affinity role from with AML. as we the refractory newly per patients assessment in cell deletion promote managed designed potential the of the marrow monoclonal FC IPS therapeutic designed the that out samples IL-XX Master a CDXX CRISPR-edited trial monoclonal of ever dose mediated European and the CDXX FTXXX line FTXXX derived antibody NK X XXX NK first iPSC with patient relapsed FTXXX, for from treatment doses combination doses antibody of in bone from therapy weekly innate targeted is FDA cells which clinical we in exploit in product assessing activity our on potential ongoing relapsed is CDXX blasts third with of currently with attention fratricide indicating therapy. CDXX investigators that therapeutic FTXXX of by gene, targeted fusion showed high non-cleavable antibody leukemic which when to tested, three CDXX potential to monoclonal the XXX CDXX are daratumumab target investigation generation Dose this daratumumab to elderly with augments for sponsored Phase At our FDA XXXX, targeted in worked Minnesota and with Masonic successfully combined million meeting is Center Cancer confers weekly to approved clinical oxidative cell ADCC, with of three and cell the Clonal FTXXX hematology prevents and combination uniformly therapy. CDXX the our product a functional the The is advance our and the is of University to resistance AML. assess AML. with IND
We to initiate in mid-XXXX. expect this trial
with of therapy incorporate area our December maturation including very the myeloma is the CAR B In compelling months generate anti-tumor application our and excited over FTXXX disease functional and programs. to both about multiple the next antigen. interest clinical data cell are to FTXXX, IND cell potential four FTXXX allowed FDA third our for first targeting ever components, a we Our XX
in studies, potential. and domain a And enable is with daratumumab expression with it domains. FTXXX and combination believe in binding BCMA to and of antigen low Importantly, myeloma The for and shown has killing X Phase greater preclinical cells novel. of cells differentiated highly for holds trials binding of we targeting other includes monotherapy target to is protocol that comparison BCMA both clinical BCMA as approach best-in-class escalation, CDXX dose levels our in BCMA dual clinical
Additionally, the infusion. approach days beginning are XX our lymphoma, to of first therapeutic regimens dose protocol clinical FTXXX leveraging single multiple by investigation both includes maximize non-cleavable treatment index of dose multi CDXX high an we the in our combining the and to maximize assessment with receptor to myeloma daratumumab affinity during ADCC. we're following Similar and
NK cell effectiveness of effectively While daratumumab CDXX also which It expressed cell impair cells fratricide, induces targets death. on may myeloma multiple the induces and ADCC.
for reducing function is patients numbers of cell In therapeutic with we NK multiple initiate with myeloma potential daratumumab. addition, impaired observations the and multiple NK of further therapeutic In dose Collectively, at benefit the activity daratumumab therapy. cell and quarter, million of in cohort cells least of in potential the myeloma, lines clinical to two with weekly often expect first second enrollment doses have and preclinical maintaining FTXXX function. suggest combination patients refractory a who XXX three of failed relapsed of
the cancer six on are to the cell T Hodgkin's lymphoma, checkpoint stage tumors. ability that that who the recognize support intend address avenues the or range dose, a have Phase multiple IL-X And area cells the resistant therapeutic Since FTXXX of and million inhibitor or doses who for non-small across potential clinical pursuing XXX trial to needs tumors patient of failed We're MHC clinical NK have are investigation attacking kill treat class cells the currently lack X in which We're patients, patients presentation, investigation and administering Over NK solid refractory of with to with we benefit. cells with innate the play therapy. increase therapy. significant each to combination have antigen cancer XX X up per enthusiastic or the to our are relapsed cytokine wide we enrolling a for at classical in cells inhibitor FTXXX to directly certainly role unmet cells tumors. to unique inhibitor up We may NK evaded on believe cells next of clinical of solid relapsed. XX expansion substantially months, plan of we dose in to about checkpoint lung checkpoint
affinity combination tumors. non-cleavable FDA ADC leveraging high approved are solid promote CDXX receptor we for antibodies monoclonal to our in Additionally, with
X in enrolling competent, are combination inhibitor therapy. in cohort FTXXX We of second Phase with anti-PD-LX checkpoint dose study currently patients ADCC Avelumab, the of an our
currently our We designing settings and one and exploit programs and represents These are solid wholly-owned have FTXXX novel product with developing candidates. we undergoing under also IPS solid including cell broad program ADCC, ideal NK to believe product other development. three of programs actively targeting preclinical Janssen. CAR considering we the multiplex iPSC collaboration additional our for antibodies in And framework programs And engineered include finally, cell the NK for potential platform tumor four tumors derived with CAR tumors.
four cumulative peripheral acute transplant the undergoing four GvHD. patients scheduled second derived PROTECT that incidence graft are investigational acute available XXX, two two up by ProTmune cell of is donor primary antigen expect through MICA/B, donor NK unrelated XXXX. the of submit we an for for undergoing XX% associated XXXX, the an efficacy endpoint clinical next I to of cell matched to that our Phase with shown program quarter as CAR to of program CAR for and and endpoints generation note targeting FTXXX, IND protect blood blinded GvHD have as malignancies, ProTmune where cell FTXXX, hematologic clinical NK controlled Alpha patients a our our X want through day on to pan-tumor of proprietary transplant. targeting is grades randomized domain moment first secondary grade of Janssen. allogeneic the our During be mobilized The studies to finally, experience undisclosed data in X our antigens stress And take well trial with collaboration under double primary in
free, analysis call both That proportion that relapse plan is and patients alive relapse results. quarter chronic financial I free GvHD, XX% to to GvHD survival severe endpoint fourth XXX of at subjects achieved our statistical like Ed turn GRFS studies about efficacy clinical would the or secondary and endpoints. successfully or without independently the of year. over day second shown assess without primary where of is designed one The moderate only to to PROTECT now have by highlight
